Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
05 2021
Historique:
received: 17 12 2020
accepted: 20 04 2021
revised: 24 05 2021
pubmed: 13 5 2021
medline: 5 10 2021
entrez: 12 5 2021
Statut: epublish

Résumé

Virus infection, such as hepatitis B virus (HBV), occasionally causes endoplasmic reticulum (ER) stress. The unfolded protein response (UPR) is counteractive machinery to ER stress, and the failure of UPR to cope with ER stress results in cell death. Mechanisms that regulate the balance between ER stress and UPR are poorly understood. Type 1 and type 2 interferons have been implicated in hepatic flares during chronic HBV infection. Here, we examined the interplay between ER stress, UPR, and IFNs using transgenic mice that express hepatitis B surface antigen (HBsAg) (HBs-Tg mice) and humanized-liver chimeric mice infected with HBV. IFNα causes severe and moderate liver injury in HBs-Tg mice and HBV infected chimeric mice, respectively. The degree of liver injury is directly correlated with HBsAg levels in the liver, and reduction of HBsAg in the transgenic mice alleviates IFNα mediated liver injury. Analyses of total gene expression and UPR biomarkers' protein expression in the liver revealed that UPR is induced in HBs-Tg mice and HBV infected chimeric mice, indicating that HBsAg accumulation causes ER stress. Notably, IFNα administration transiently suppressed UPR biomarkers before liver injury without affecting intrahepatic HBsAg levels. Furthermore, UPR upregulation by glucose-regulated protein 78 (GRP78) suppression or low dose tunicamycin alleviated IFNα mediated liver injury. These results suggest that IFNα induces ER stress-associated cell death by reducing UPR. IFNγ uses the same mechanism to exert cytotoxicity to HBsAg accumulating hepatocytes. Collectively, our data reveal a previously unknown mechanism of IFN-mediated cell death. This study also identifies UPR as a potential target for regulating ER stress-associated cell death.

Identifiants

pubmed: 33979382
doi: 10.1371/journal.ppat.1009228
pii: PPATHOGENS-D-20-02684
pmc: PMC8143404
doi:

Substances chimiques

Endoplasmic Reticulum Chaperone BiP 0
HSPA5 protein, human 0
Hepatitis B Surface Antigens 0
Hspa5 protein, mouse 0
Interferon-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009228

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Virol. 2010 Dec;84(24):12850-61
pubmed: 20881037
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9
pubmed: 19033462
Gastroenterology. 2008 Mar;134(3):716-26
pubmed: 18325387
J Neurosci Res. 2000 Jan 15;59(2):160-9
pubmed: 10650874
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6909-13
pubmed: 3477814
Virology. 2009 Sep 1;391(2):257-64
pubmed: 19628242
Hepatology. 1992 Sep;16(3):655-63
pubmed: 1505908
Nat Cell Biol. 2000 Jun;2(6):326-32
pubmed: 10854322
J Virol. 2002 Aug;76(15):7453-9
pubmed: 12097557
J Biol Chem. 2004 Apr 23;279(17):17158-64
pubmed: 14960590
J Exp Med. 2007 Mar 19;204(3):667-80
pubmed: 17353365
Front Cell Dev Biol. 2017 May 10;5:48
pubmed: 28540288
Am J Physiol Gastrointest Liver Physiol. 2015 Dec 15;309(12):G965-74
pubmed: 26472223
J Virol. 1995 Oct;69(10):6158-69
pubmed: 7666518
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents
pubmed: 11585785
Bioinformatics. 2006 May 1;22(9):1096-102
pubmed: 16481333
Cold Spring Harb Perspect Med. 2014 Nov 03;4(11):a021550
pubmed: 25368018
Genes Dev. 1998 Apr 1;12(7):982-95
pubmed: 9531536
Nat Rev Drug Discov. 2013 Sep;12(9):703-19
pubmed: 23989796
Nature. 2019 Oct;574(7777):200-205
pubmed: 31582858
Semin Cell Dev Biol. 1999 Oct;10(5):465-72
pubmed: 10597629
J Immunol. 2009 Jan 1;182(1):391-7
pubmed: 19109170
Gastroenterology. 1992 Mar;102(3):956-62
pubmed: 1537531
Semin Liver Dis. 2019 May;39(2):235-248
pubmed: 30912096
J Clin Invest. 2002 Feb;109(4):525-32
pubmed: 11854325
Front Microbiol. 2014 Jun 03;5:266
pubmed: 24917859
Nat Rev Cancer. 2014 Apr;14(4):263-76
pubmed: 24658275
Cell. 2009 Jul 23;138(2):377-88
pubmed: 19632185
J Hepatol. 2007 Aug;47(2):183-90
pubmed: 17448568
Hepatology. 1991 Jan;13(1):150-7
pubmed: 1988336
J Exp Med. 1993 Nov 1;178(5):1541-54
pubmed: 8228807
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6669-74
pubmed: 15100412
Cell. 2001 Dec 28;107(7):881-91
pubmed: 11779464
FEBS J. 2007 Feb;274(3):630-58
pubmed: 17288551
Hepatology. 2018 Aug;68(2):473-484
pubmed: 29572897
PLoS Pathog. 2013;9(7):e1003490
pubmed: 23853599
Cell Microbiol. 2017 May;19(5):
pubmed: 28207988
FEBS J. 2018 Mar;285(6):995-1011
pubmed: 29148236
Science. 2011 Nov 25;334(6059):1081-6
pubmed: 22116877
J Hepatol. 2010 Mar;52(3):330-9
pubmed: 20137825
J Biol Chem. 2015 Dec 11;290(50):30142-51
pubmed: 26504083
Nat Rev Cancer. 2014 Sep;14(9):581-97
pubmed: 25145482
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Cell Death Differ. 2006 Mar;13(3):374-84
pubmed: 16397578
J Virol. 2006 Mar;80(6):2797-807
pubmed: 16501088
Immunity. 2006 Sep;25(3):373-81
pubmed: 16979569
Hepatology. 2006 Oct;44(4):915-24
pubmed: 17006908
Virol J. 2011 Jul 20;8:359
pubmed: 21774819
Mol Biol Cell. 2011 Nov;22(22):4390-405
pubmed: 21917591
Cancer Cell. 2014 Sep 8;26(3):331-343
pubmed: 25132496
Aliment Pharmacol Ther. 2016 Jan;43(1):145-53
pubmed: 26526395
Gastroenterology. 2004 Apr;126(4):1024-9
pubmed: 15057742
Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29
pubmed: 17565364
J Virol. 1987 Mar;61(3):782-6
pubmed: 3806798
Mol Cell. 2000 May;5(5):897-904
pubmed: 10882126

Auteurs

Ian Baudi (I)

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Masanori Isogawa (M)

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.

Federica Moalli (F)

Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Masaya Onishi (M)

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.

Keigo Kawashima (K)

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.

Yuji Ishida (Y)

Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
PhoenixBio Co., Ltd., Higashi-Hiroshima, Japan.

Chise Tateno (C)

Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
PhoenixBio Co., Ltd., Higashi-Hiroshima, Japan.

Yusuke Sato (Y)

Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Hideyoshi Harashima (H)

Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Hiroyasu Ito (H)

Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan.

Tetsuya Ishikawa (T)

Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takaji Wakita (T)

National Institute of Infectious Diseases, Tokyo, Japan.

Matteo Iannacone (M)

Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Yasuhito Tanaka (Y)

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH